Benjamin Enerson
Algemeen Adviseur bij THESEUS PHARMACEUTICALS, INC.
Profiel
Benjamin Enerson is currently working as Vice President-Legal Affairs at Theseus Pharmaceuticals, Inc. Prior to this, he worked as General Counsel at Finch Therapeutics Group, Inc. and Tremeau Pharmaceuticals, Inc. He completed his undergraduate degree from Vanderbilt University and his graduate degree from Cornell Law School in 2004.
Actieve functies van Benjamin Enerson
| Bedrijven | Functie | Begin |
|---|---|---|
| THESEUS PHARMACEUTICALS, INC. | Algemeen Adviseur | - |
Eerdere bekende functies van Benjamin Enerson
| Bedrijven | Functie | Einde |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Algemeen Adviseur | - |
Tremeau Pharmaceuticals, Inc.
 Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Algemeen Adviseur | - |
Opleiding van Benjamin Enerson
| Cornell Law School | Graduate Degree |
| Vanderbilt University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Bedrijven in privébezit | 2 |
|---|---|
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
Tremeau Pharmaceuticals, Inc.
Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Health Technology |